The Louisiana Court of Appeal recently upheld a trial court's decision to dismiss a medical malpractice case involving Tina Crow and her husband, Isaac Crow, Jr. The court ruled that the case must first go before a medical review panel, as required by state law. This ruling affects the Crows' claims against Bioscript Pharmacy, LLC, and Option Care Enterprises, Inc., regarding an alleged overdose of medication.
The case, filed under docket number 56,969-CA, centers around an incident in which Mr. Crow allegedly suffered harm due to an increased dosage of an antibiotic without proper authorization. The court's decision is significant as it reinforces the legal requirement for medical malpractice claims to undergo a review process before proceeding to court.
Background
Tina Crow filed a petition for damages on May 12, 2025, on behalf of her husband, Isaac Crow, Jr., against Bioscript Pharmacy, LLC, alleging personal injury related to an antibiotic overdose. After an amendment to the petition, Option Care Enterprises, Inc. was named as the proper defendant. The Crows claimed that Mr. Crow suffered harm due to an unauthorized increase in his medication dosage.
The Crows' legal journey began with a motion for default judgment filed on July 11, 2025. However, Option Care responded by asserting that the claims required submission to a medical review panel under the Louisiana Medical Malpractice Act (LMMA). Following a series of court hearings and motions, the trial court granted Option Care's exception of prematurity, dismissing the case without prejudice on November 7, 2025. The Crows appealed this decision.
The Ruling
The Louisiana Court of Appeal, led by Judge Robinson, affirmed the trial court's ruling. The court noted that the claims made by the Crows fell under the category of medical malpractice, which necessitates a review panel according to the LMMA. The court stated, "The Crows’ claims, as supported by the record versus merely alleged in the pleadings, clearly sound in medical malpractice rather than intentional tort and/or fraud."
The ruling emphasized that the Crows did not provide sufficient evidence to support their claims of fraud or intentional misconduct. Instead, the court found that the increase in medication dosage was authorized by a physician, Dr. Malek, and the misidentification of the prescribing physician was determined to be a human error by the Louisiana Board of Pharmacy.
Impact
This ruling has significant implications for the Crows and others in similar situations. By affirming the requirement for a medical review panel, the court reinforced the procedural steps necessary for medical malpractice claims in Louisiana. This means that individuals alleging malpractice must first submit their claims for review before they can pursue legal action in court.
The decision may also discourage other potential plaintiffs from pursuing similar claims without first adhering to the LMMA's requirements. It highlights the importance of following legal protocols in medical malpractice cases, which can significantly impact the outcome of such claims.
What's Next
The Crows may consider appealing the decision to a higher court, but details were not available in the court filing regarding any pending related cases. The ruling sets a precedent for how medical malpractice claims are handled in Louisiana, emphasizing the necessity of a review process before litigation.